Nasdaq:US$42.05 (+1.07) | HKEX:HK$70.60 (-7.00) | AIM:£5.95 (+0.03)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors